Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer [Phase 2]
This entry reports a Phase 2 trial evaluating adjunctive intravenous ascorbic acid for advanced non-small cell lung cancer, which is current…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib [Phase 1, Phase 2]
A Phase 1/2a clinical study evaluating GEN-725 in combination with Dositinib is currently recruiting for non-small cell lung cancer.
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer [NA]
This item reports an ongoing clinical trial at Thomas Jefferson University examining the impact of surgical technique on circulating tumor D…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Zorifertinib With Osimertinib for NSCLC With Meningeal Progression [Phase 1]
The document reports a Phase 1 clinical trial evaluating Zorifertinib in combination with Osimertinib for patients with advanced non-small c…
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: SLV-154 Treatment of Metastatic Solid Tumors [Phase 1]
Phase 1 clinical trial update for SLV-154 evaluating treatment of metastatic solid tumors. The study is currently recruiting across multiple…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. [Phase 3]
This update notes a Phase 3 trial evaluating SCTB14 as first-line therapy for non-small cell lung cancer, which is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) [Phase 3]
A Phase 3 neoadjuvant trial (IMpower030) evaluating atezolizumab plus chemotherapy versus chemotherapy alone in resectable non-small cell lu…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 2, Phase 3]
A study to determine whether adding fianlimab to cemiplimab improves outcomes versus cemiplimab alone in adults with advanced non-small cell…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: First in Human Study of QLS5316 in Solid Tumors [Phase 1]
This is a first-in-human Phase 1 trial of QLS5316 in various solid tumors; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer [NA]
A completed clinical trial examining the relationship between circulating immune cells and the tumor immune contexture in patients with rese…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
A phase 1/2 study of TAK-500 with or without pembrolizumab in adults with select locally advanced or metastatic solid tumors; the trial was …
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating safety and efficacy of adding Durvalumab with consolidative hypofractionated radiotherapy for residual n…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases [Phase 2]
Phase 2 study of tiragolumab plus atezolizumab in non-squamous non-small cell lung cancer with untreated brain metastases has been terminate…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer [Phase 2]
A Phase 2 trial assessing osimertinib plus selumetinib in EGFR-mutant, EGFR-inhibitor naive advanced non-small cell lung cancer is currently…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer [Phase 3]
A Phase 3 clinical trial comparing different surgical approaches for stage IA non-small cell lung cancer has completed.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1]
Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of HJ-004-02 tablets in patients with n…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial evaluating OCT-598 in patients with advanced solid tumors; the study is currently recruiting and includes multiple tu…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies [Phase 4]
Phase 4 clinical trial evaluating safety and quality of life in elderly patients with advanced/metastatic cancer undergoing immunotherapy ha…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer [Phase 2, Phase 3]
This entry reports an ongoing Phase 2/Phase 3 clinical trial evaluating the combination of fianlimab with cemiplimab and chemotherapy versus…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC [Phase 2]
Phase II trial evaluating HLX43 plus serplulimab as neoadjuvant therapy for non-small cell lung cancer; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating toripalimab in combination with platinum-based chemotherapy, with or without an H1 receptor antagonist, as…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI [Phase 1, Phase 2]
This clinical trial update reports an early-phase study evaluating lung functional avoidance radiotherapy guided by hyperpolarized xenon MRI…
-
CLINICAL_TRIALS other · 2026-01-22Clinical Trial Update: An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. [Phase 4]
Open-label, single-arm Phase 4 trial assessing prophylaxis for datopotamab deruxtecan–related stomatitis in patients with metastatic or inop…
-
EMA approval · 2026-01-21EMA Authorised: Abraxane (paclitaxel) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Abraxane (paclitaxel) by Bristol-Myers Squibb Pharma EEIG for breast cancer, pancreatic cancer, and non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg [Phase 2]
Phase 2 trial of Firmonertinib in EGFR-mutant advanced non-small cell lung cancer shows disease stabilization after an 8-week induction with…